Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production

Pathogenic and Therapeutic Implications

Yuji Yoshida,1 Atsushi Ogata,1 Sujin Kang,1 Kousuke Ebina,1 Kenrin Shi,2 Satoshi Nojima,1 Tetsuya Kimura,1 Daisuke Ito,1 Keiko Morimoto,1 Masayuki Nishide,1 Takashi Hosokawa,1 Toru Hirano,1 Yoshihito Shima,1 Masashi Narazaki,1 Hideki Tsuboi,3 Yukihiko Saeki,3 Tetsuya Tomita,1 Toshio Tanaka,1 and Atsushi Kumanogoh1

Objective. Semaphorin 4D (Sema4D)/CD100 has pleiotropic roles in immune activation, angiogenesis, bone metabolism, and neural development. We undertook this study to investigate the role of Sema4D in rheumatoid arthritis (RA).

Methods. Soluble Sema4D (sSema4D) levels in serum and synovial fluid were analyzed by enzyme-linked immunosorbent assay. Cell surface expression and transcripts of Sema4D were analyzed in peripheral blood cells from RA patients, and immunohistochemical staining of Sema4D was performed in RA synovium. Generation of sSema4D was evaluated in an ADAMTS-4–treated monocytic cell line (THP-1 cells). The efficacy of anti-Sema4D antibody was evaluated in mice with collagen-induced arthritis (CIA).

Results. Levels of sSema4D were elevated in both serum and synovial fluid from RA patients, and disease activity markers were correlated with serum sSema4D levels. Sema4D-expressing cells also accumulated in RA synovium. Cell surface levels of Sema4D on CD3+ and CD14+ cells from RA patients were reduced, although levels of Sema4D transcripts were unchanged. In addition, ADAMTS-4 cleaved cell surface Sema4D to generate sSema4D in THP-1 cells. Soluble Sema4D induced tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) production from CD14+ monocytes. IL-6 and TNFα induced ADAMTS-4 expression in synovial cells. Treatment with an anti-Sema4D antibody suppressed arthritis and reduced proinflammatory cytokine production in CIA.

Conclusion. A positive feedback loop involving sSema4D/IL-6 and TNFα/ADAMTS-4 may contribute to the pathogenesis of RA. The inhibition of arthritis by anti-Sema4D antibody suggests that Sema4D represents a potential therapeutic target for RA.

Rheumatoid arthritis (RA) is a common autoimmune disease that causes chronic inflammation of the synovium. RA synovitis evokes arthritis symptoms and leads to destruction of cartilage and bone in joints.
Recent advances in understanding the pathogenesis of RA have revealed that complex interplay between genetic and environmental factors evoke autoimmunity, accompanied by the production of critical autoantigens such as citrullinated proteins (1,2). Once RA has developed, autoimmunity is sustained and leads to persistent synovitis, which in turn causes destruction of bone and cartilage (3,4). The mechanisms of sustained synovitis remain unclear. Recently, proinflammatory cytokines such as tumor necrosis factor \( \alpha \) (TNF\( \alpha \)) and interleukin-6 (IL-6) were shown to have key roles in RA. Biologic disease-modifying antirheumatic drugs (DMARDs), which can block these cytokines, constitute the current standard of care (5,6). However, a substantial proportion of RA patients still do not achieve drug-free remission of their disease, it will be necessary to identify another key molecular player that contributes to autoimmunity, immune activation, and bone destruction in RA.

Semaphorins were originally identified as neural guidance factors (7). The semaphorin family consists of more than 20 proteins, categorized into 8 subclasses based on their structural features (8). Recent research on semaphorins demonstrated that these proteins have pleiotropic roles, including regulation of immune responses (9,10), angiogenesis (11,12), tumor metastasis (13,14), and bone metabolism (15–17). Semaphorins involved in various aspects of immune responses are referred to as “immune semaphorins” (18). Previous studies have shown that immune semaphorins have important roles in immunologic disorders, including multiple sclerosis (MS), airway hypersensitivity, granulomatosis with polyangiitis (Wegener’s) (GPA), and RA (9,10). For instance, the level of soluble semaphorin 4A (sSema4A) is elevated in the serum of MS patients, in which Th17 cell populations are also increased (19). Recently, a Sema4A variant was identified as a significant contributor to the risk of GPA (20). In addition, serum levels of Sema3A and Sema5A have been suggested to be relevant to RA (21–23). However, the pathologic significance of semaphorins in autoimmunity remains unclear.

Sema4D/CD100 was the first semaphorin shown to have a role in the immune system (24–26), and it was originally identified as a T cell activation marker (24). Indeed, Sema4D is abundantly expressed on the surface of T cells (24); however, it is also expressed in a broad range of hematopoietic cells. Although Sema4D is a membrane-bound protein, it also exists as a functional soluble form (sSema4D) following proteolytic cleavage upon cellular activation (27,28). Sema4D binds several receptors, plexin B1/B2, CD72, and plexin C1, which mediate the effects of Sema4D on neural cells, immune cells, endothelial cells, and epithelial cells (25,29). Several studies have demonstrated that Sema4D has crucial roles in the immune system. For example, Sema4D promotes activation of B cells and antibody production by B cells (30), Sema4D expressed on dendritic cells (DCs) is involved in antigen-specific T cell priming (31), Sema4D induces cytokine production by monocytes (32), and Sema4D mediates retrograde signals in mediating restoration of epithelium integrity (29).

Several studies have shown that Sema4D is relevant to the pathogenesis of autoimmunity. For instance, Sema4D-deficient mice are resistant to the development of experimental autoimmune encephalomyelitis (33), a murine model of MS. Sema4D is expressed on tumor-associated macrophages, and Sema4D produced by tumor-associated macrophages is involved in tumor angiogenesis and vessel maturation (34). Notably, Sema4D derived from osteoclasts suppresses bone formation by osteoblasts, and blocking of Sema4D results in increased bone mass (15). Immune abnormality, angiogenesis, and bone destruction all have critical roles in the progression of RA (35,36), suggesting that Sema4D might exacerbate RA. However, the involvement of Sema4D in the pathogenesis of RA has not yet been determined.

In this study, we found that sSema4D levels were elevated in serum and synovial fluid from RA patients. The increased levels of sSema4D were produced by an inflammation-related proteolytic mechanism, and the resultant sSema4D in turn induced inflammation, suggesting the existence of an inflammatory activation loop in RA synovium. Inhibition of Sema4D ameliorated the symptoms of collagen-induced arthritis (CIA). These results suggest that Sema4D represents a potential target for treatment of RA.

**SUBJECTS AND METHODS**

**Subjects.** Blood samples were obtained from 101 patients with RA, 34 with systemic lupus erythematosus (SLE), 10 with ankylosing spondylitis (AS), and 10 with osteoarthritis (OA) at Osaka University Hospital and National Hospital Organization Osaka Minami Medical Center. Patients with RA were diagnosed according to the 1987 revised criteria of the American College of Rheumatology (37). Blood samples were also obtained from healthy individuals recruited from university staff, hospital staff, and the student population. Seven RA and 10 OA synovial tissue samples were obtained from patients undergoing synovectomy or knee replacement, and RA and OA synovial fluid samples were obtained from patients undergoing knee arthrocentesis. All samples were obtained after informed consent was provided by the subjects in accordance with the Declaration of Helsinki and with approval from the local ethics committees of Osaka University Hospital and National Hospital Organization Osaka Minami Medical Center.
This study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000013076).

**Enzyme-linked immunosorbent assays (ELISAs).** Soluble Sema4D levels in serum and synovial fluid samples and cell culture supernatants were measured using an ELISA kit (MyBioSource). Serum and synovial fluid samples were stored at −20°C prior to ELISAs. The lower detection limit of Sema4D was 125 pg/ml. Levels of ADAMTS-4 in serum and synovial fluid samples were also determined using an ELISA kit (MyBioSource). The concentrations of human TNFα and IL-6 in culture supernatants were determined using DuoSet ELISA kits for each cytokine (R&D Systems).

**Histology.** Immunohistochemical staining was performed on 7 RA and 10 OA synovial tissue samples. Briefly, sections were deparaffinized and subjected to antigen retrieval by autoclaving in 10 mM citrate buffer (pH 6.0) for 15 minutes at 125°C, after which endogenous peroxidase activity was blocked with Dako REAL peroxidase blocking solution. Sections were allowed to react overnight with mouse anti-Sema4D polyclonal antibody (1:100; BD Biosciences), mouse anti-CD3 monoclonal antibody (1:100; Dako), Ready-to-Use mouse anti-CD20 monoclonal antibody (1:1; Dako), and Ready-to-Use mouse negative control Ig cocktail (1:1; Dako) or rabbit anti-CD31 polyclonal antibody (1:50; Abcam). Slides were then incubated with a peroxidase-labeled polymer conjugated to secondary anti-rabbit antibodies using EnVisionTM/HRP (Dako) and then developed with 3,3-diaminobenzidine as the chromogen.

**Cell preparations.** Human peripheral blood mononuclear cells (PBMCs) were separated by density-gradient centrifugation using Ficoll-Paque Plus (GE Healthcare Biosciences). CD14+ monocytes were collected using CD14 MicroBeads (Miltenyi Biotec), yielding >90% CD14+ cells.

**Flow cytometry.** PBMCs were prepared in heparinized tubes by Ficoll-Paque density-gradient centrifugation and then analyzed on a FACS Canto (BD Biosciences) using FlowJo software (Tree Star). To prevent nonspecific binding, cells (2 × 106) were incubated with human AB serum (Lonza) for 45 minutes at 4°C and then labeled with antibodies against indicated cell surface antigens. The following antibodies were used: fluorescein isothiocyanate-conjugated anti-human Sema4D (A8; BioLegend), phycoerythrin (PE)-conjugated anti-human CD3 (HIT3a; BioLegend), PE-conjugated anti-human CD14 (M5E2; BioLegend), and PE-conjugated anti-human CD19 (HIB19; Tonbo Biosciences).

**Quantitative reverse transcription–polymerase chain reaction (qRT-PCR).** CD3+, CD19+, or CD14+ cells (1 × 106) were sorted using a FACS Aria (BD Biosciences). Total RNA was extracted using an RNeasy Mini kit (Qiagen), and complementary DNA (cDNA) was synthesized using a SuperScript II cDNA synthesis kit (Invitrogen). Quantitative RT-PCR analysis was performed on a 7900HT Fast Real-Time PCR system (Applied Biosystems) using a TaqMan PCR protocol. Assay ID numbers for TaqMan primer sets (Applied Biosystems) were Hs00174819_m1 for human SEMA4D and Hs00192708_m1 for human ADAMTS4. Expression levels of tested genes were normalized to that of the housekeeping gene ACTB (Hs01060665_g1) and calculated using the ΔΔCt method.

**Shedding of sSema4D.** The monocytic cell line THP-1 and PBMCs from RA patients were cultured at 37°C for 12 hours in 96-well plates at a density of 5 × 104 cells/ml in RPMI 1640 medium containing 10 μg/ml of matrix metalloproteinase 3 (MMP-3; Sigma-Aldrich), MMP-9 (R&D Systems), ADAM-17 (R&D Systems), and ADAMTS-4 (R&D Systems). Soluble Sema4D concentrations were measured using an ELISA kit (MyBioSource).

**Isolation of synovial cells and stimulation by IL-6 and TNFα.** Samples of knee articular synovium were obtained from RA patients. Synovial tissues were chopped finely and then digested for 45 minutes with continuous stirring at 37°C with collagenase D (800 Mandll units/ml; Roche) and dispase I (10 mg/ml; Invitrogen) in RPMI 1640 medium containing 5% fetal calf serum (FCS). After digestion, the samples were filtered through a cell strainer (BD Biosciences). Adherent synovial cells were harvested and passed into another dish. For experiments, synovial cells at passages 2–3 were seeded in 96-well plates at 1 × 105 cells per well and then stimulated for 2 days with 1 μg/ml of IL-6 and 0.1 μg/ml of TNFα (PeproTech) in Dulbecco’s modified Eagle’s medium containing 10% FCS. At the end of the stimulation period, cells were collected, and messenger RNA (mRNA) was extracted. Quantitative RT-PCR analysis of ADAMTS-4 was performed as described above. Concentrations of ADAMTS-4 in culture supernatants were also measured by ELISA.

**Monocyte culture and cytokine assays.** CD14+ monocytes from RA patients (1 × 106) were stimulated with or without various concentrations of soluble human Sema4D-Fc fusion protein, naturally cleaved Sema4D, or CD72 ligation antibody (BU40; Santa Cruz Biotechnology). For blocking experiments, cells were cocultured with 1 μg/ml of naturally cleaved Sema4D and 10 μg/ml of anti-Sema4D/CD100 antibody (3E9) (33) or isotype-matched control IgG for 48 hours. Concentrations of human TNFα and IL-6 in culture supernatants were determined by ELISA.

Human Sema4D-Fc fusion protein and sSema4D were produced and purified as previously described (28,32), and Recombinant Human IgG1 Fc (R&D Systems) was used as a control. Naturally cleaved Sema4D was affinity-purified using a column containing CNBr-activated Sepharose 4 Fast Flow resin (Amersham Pharmacia Biotech) conjugated to anti-Sema4D monoclonal antibody (A8) as described previously (28).

**Induction and assessment of CIA.** Eight-week-old male DBA/1J mice were purchased from Oriental Yeast Company. Bovine type II collagen (2 mg/ml; Chondrex) was dissolved in 0.05M acetic acid and emulsified with an equal volume of Freund’s complete adjuvant (Sigma-Aldrich). Mice were immunized by intradermal injection at the base of the tail with 100 μl (2 mg/ml) of the emulsion (day 0). Booster injections of 100 μl of emulsion consisting of equal parts of Freund’s incomplete adjuvant (Sigma-Aldrich) and 2 mg/ml type II collagen in 0.05M acetic acid were administered at another site at the base of the tail on day 21. Mice with CIA received intraperitoneal injections of 50 mg/kg anti-Sema4D antibody (BMA-12) (30) (n = 6), 25 mg/kg anti-Sema4D antibody (n = 8), or isotype control antibodies (Chugai Pharmaceutical) on day 28 and day 35. Serum was collected on day 42. Serum levels of IL-6, TNFα, and IL-1β were determined using a Bio-Plex Pro Mouse Cytokine Assay (Bio-Rad).

Serum titers of type II collagen antibodies were detected by ELISA (Chondrex). Arthritis clinical scores were determined on a scale of 0–4 for each paw (0 = normal;
erythema and swelling of 1 digit; 2 = erythema and swelling of 2 digits or erythema and swelling of the ankle joint; 3 = erythema and swelling of 3 digits or swelling of 2 digits and the ankle joint; and 4 = erythema and severe swelling of the ankle, foot, and digits with deformity). Two paws of each mouse were evaluated histologically. Joint pathology was assessed and quantitated as described previously (38). The paws of mice treated with anti-Sema4D antibody (n = 12), control antibody (n = 12), or no antibody (n = 12) were stained with anti-CD31 antibodies. Vessels were counted manually in 5 fields (40×) per paw and averaged. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Osaka University.

**Statistical analysis.** Data are expressed as the mean ± SD or mean ± SEM. Nonparametric Mann-Whitney U tests were used to compare 2 groups, and comparisons between 3 groups were performed using the Kruskal-Wallis test followed by the Mann-Whitney U test. P values less than or equal to 0.05 were considered significant. Correlations between clinical parameters and serum sSema4D levels were determined using Pearson’s correlation coefficient (r).

**RESULTS**

Elevation of sSema4D levels in RA, and accumulation of Sema4D-expressing cells in RA synovium. To investigate the pathologic implications of Sema4D in RA, we first measured the serum concentrations of Sema4D in patients with several autoimmune and joint-destructive diseases. As shown in Figure 1A, serum sSema4D levels were significantly higher in RA patients than in healthy individuals (mean ± SD 11.2 ± 8.4 ng/ml versus 5.6 ± 2.7 ng/ml; P < 0.001) (demographics and characteristics of RA patients are shown in Supplementary Table 1, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract). In contrast, serum sSema4D levels were not elevated in patients with OA, AS, or SLE (mean ± SD 5.2 ± 2.4 ng/ml, 4.9 ± 2.3 ng/ml, and 7.0 ± 2.6 ng/ml, respectively). Notably, Sema4D levels were also
elevated in the synovial fluid of RA patients (mean ± SD 11.8 ± 7.0 ng/ml), but Sema4D was undetectable in the synovial fluid of OA patients (P < 0.01) (Figure 1B).

Immunohistochemical staining revealed accumulation of Sema4D-positive cells in RA synovium, clustered mainly in follicle-like germinal centers. However, such accumulation and clustering of Sema4D-expressing cells were not observed in OA synovium (Figure 1C). CD3 and CD20 were colocalized in Sema4D-stained follicle-like germinal centers, indicating that the Sema4D-expressing cells were synovial infiltrating lymphocytes (see Supplementary Figure 1, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract). In contrast, CD68+ macrophages faintly expressed Sema4D. Additionally, the distribution of CD68+ cells was patchy, and their localization patterns were different from those of T and B cells.

**Correlation of serum sSema4D levels with RA disease activity and biomarkers.** To determine the clinical implications of sSema4D, we examined the correlations between serum sSema4D levels and clinical features. Table 1 summarizes the correlations between patients' clinical features and serum sSema4D levels. There were no apparent correlations between sSema4D levels and age, sex, disease duration, or medications (data not shown). In contrast, serum sSema4D levels were positively correlated with disease activity markers such as the Disease Activity Score in 28 joints (DAS28) (39) (r = 0.383, P < 0.01), the C-reactive protein (CRP) level (r = 0.346, P < 0.01), and the rheumatoid factor (RF) titer (r = 0.328, P < 0.01). In addition, levels of bone metabolic markers such as bone alkaline phosphatase (BAP) (r = 0.255, P < 0.05) and urinary deoxypyridinoline (r = 0.318, P < 0.05) correlated with serum sSema4D levels.

Scatterplots confirmed the relationships between serum levels of sSema4D and the disease activity markers (Figure 2A). Sequential analysis of serum sSema4D levels was performed in RA patients treated with biologic DMARDs (n = 17); specifically, serum levels of sSema4D were evaluated before and 6 months after initiation of biologic DMARD therapy (14 patients were treated with TNF inhibitors, and 3 patients were treated with tocilizumab). A significant decrease in serum sSema4D levels after biologic DMARD treatment was observed in patients who were good responders according to the European League Against Rheumatism response criteria (40) (Figure 2B). In contrast, sSema4D levels were not changed in patients with a moderate response or no response (Figure 2B). The posttreatment change ratio of Sema4D after biologic DMARD treatment was significantly correlated with the change ratio of the DAS28 (r = 0.799, P < 0.001) (Figure 2C), suggesting the involvement of Sema4D in determining the clinical status of RA. The reductions in serum sSema4D levels did not differ significantly between patients treated with TNF inhibitors and those treated with an IL-6 inhibitor. Thus, the reduction in serum sSema4D levels simply correlated with reduction in disease activity.

**Shedding of Sema4D in RA patients.** Sema4D is abundantly expressed in T cells but weakly expressed in other cell types such as B cells (24). Sema4D is also expressed on antigen-presenting cells, including macrophages and DCs (32). As shown in Figure 1C, we observed Sema4D-expressing cells in the synovium. Next, we examined Sema4D expression in PBMCs from RA patients and healthy individuals. In healthy individuals, cell surface Sema4D was expressed abundantly on CD3+ and CD14+ cells and at lower levels on CD19+ cells (Figure 3A). Furthermore, the cell surface expression of Sema4D was down-regulated on all cells from RA patients, especially on cells positive for CD3 or CD14. In contrast, qRT-PCR revealed that the expression of mRNA for Sema4D was not reduced in RA patients (Figure 3B), suggesting that the reduction in cell surface Sema4D was due to shedding of Sema4D from the cell surface.

Previous studies showed that although Sema4D is a membrane-bound protein, it can be cleaved from the cell surface by metalloproteinases to yield a soluble form (27). Therefore, we examined the proteolytic cleavage of Sema4D. ADAMs, ADAMTS, and MMPs are proteolytic enzymes that digest extracellular matrix proteins such as collagen, and they process bioactive substances that have a physiologic role in RA (41). We incubated
Sema4D-expressing cells (THP-1 cells) with recombinant metalloproteinases including MMP-3, MMP-9, ADAM-17, and ADAMTS-4, and then we measured sSema4D levels in the culture supernatants. ADAMTS-4 significantly induced the release of sSema4D into the culture supernatant (Figure 3C) (see Supplementary Figure 2, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract). Consistent with this, we detected elevated levels of ADAMTS-4 in serum and synovial fluid in the RA patients examined in this study (Figures 3D and E).

Proinflammatory cytokine production by sSema4D. To determine the pathogenic role of elevated sSema4D levels in RA, we investigated the effect

---

**Figure 2.** Correlations of serum levels of soluble semaphorin 4D (sSema4D) with markers of rheumatoid arthritis disease activity. **A,** Positive correlation of serum sSema4D levels with the Disease Activity Score in 28 joints (DAS28), the C-reactive protein (CRP) level, the rheumatoid factor (RF) titer, and the level of urinary deoxypyridinoline (u-DPD). **B,** Serum sSema4D levels before and after biologic disease-modifying antirheumatic drug (DMARD) treatment in 9 good responders and 8 moderate responders or nonresponders according to the European League Against Rheumatism response criteria. ***P = 0.001. NS = not significant. **C,** Correlation of change ratio in serum sSema4D levels with change ratio of DAS28 after treatment with biologic DMARDs (n = 17 samples).

**Figure 3.** Semaphorin 4D (Sema4D) expression, and soluble Sema4D (sSema4D) production with ADAMTS-4 as the sheddase. **A,** Histograms of cell surface expression of Sema4D in peripheral blood CD3+, CD19+, and CD14+ cells. Results shown are representative of findings from 5 rheumatoid arthritis (RA) patients and 5 healthy individuals. **B,** Expression of mRNA for Sema4D in peripheral blood CD3+, CD19+, and CD14+ cells. Results shown are from 5 RA patients and 5 healthy individuals. **C,** Levels of sSema4D in culture supernatant of THP-1 cells cultured with recombinant matrix metalloproteinase 3 (MMP-3), MMP-9, ADAM-17, and ADAMTS-4 (n = 5 samples per group). Results are representative of 3 independent experiments. **D,** Serum levels of ADAMTS-4 in 20 RA patients and 16 healthy individuals. **E,** Synovial fluid levels of ADAMTS-4 in 7 RA patients and 10 osteoarthritis (OA) patients. Values in **B–E** are the mean ± SEM. **P < 0.01. NS = not significant.
of sSema4D on TNFα and IL-6 production. Treatment with naturally cleaved sSema4D increased production of TNFα and IL-6 by CD14+ monocytes in a dose-dependent manner (Figure 4A). In addition, recombinant sSema4D-Fc fusion protein also induced TNFα and IL-6 production by PBMCs in a dose-dependent manner (see Supplementary Figure 3, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract). Moreover, anti-Sema4D antibody suppressed TNFα and IL-6 production induced by sSema4D (Figure 4B). CD72 is a receptor for Sema4D, and a CD72 ligation antibody also induced TNFα and IL-6 production in CD14+ monocytes, in which Sema4D induced dephosphorylation of CD72 (see Supplementary Figures 4 and 5, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract).

Because previous studies showed that inflammatory cytokines induce ADAMTS-4 in synovial cells (42), we examined ADAMTS-4 production in TNFα- and IL-6–stimulated synovial cells. TNFα and IL-6 treatment increased mRNA and protein levels of ADAMTS-4 (Figures 4C and D). These results not only indicated that sSema4D can induce the production of proinflammatory cytokines but also implied that such cytokines in turn up-regulate the cleavage of Sema4D by ADAMTS-4.

Amelioration of CIA severity by blocking of Sema4D. To determine the pathologic roles of Sema4D in arthritis, we examined the effect of anti-Sema4D antibody treatment on CIA. Arthritis scores in anti-Sema4D antibody–treated mice were significantly lower than those in control mice (Figure 5A), and the decrease in arthritis scores was attenuated in mice treated with half a dose of antibody (see Supplementary Figure 6, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract). Histologic analysis revealed that blocking Sema4D in mice with CIA also reduced inflammatory infiltration into the synovium, decreased pannus formation, and ameliorated erosion of adjacent cartilage and bone (Figure 5B). Histologic scores in the joints of anti-Sema4D antibody–treated mice were significantly reduced (Figure 5C). Furthermore, serum TNFα and IL-6 levels on day 42 were significantly reduced in anti-Sema4D antibody–treated mice (Figure 5D). We evaluated angiogenesis by antibody staining for CD31, a marker of blood vessel endothelium. Mice treated with anti-Sema4D antibody exhibited poor induction of angiogenesis at sites of inflammation (see Supplementary Figures 7A and B, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract). Additionally, the serum level of anticollagen antibody was reduced in these animals (see Supplementary Figure 8, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract).

**DISCUSSION**

In this study, we investigated the clinical implications of sSema4D in RA. Levels of sSema4D were elevated in RA serum and synovial fluid. However, sSema4D levels were not elevated in OA and SLE, suggesting that
high sSema4D levels are specifically associated with RA. Serum sSema4D levels correlated with known clinical and biologic markers of RA (Table 1). In particular, serum sSema4D levels correlated with the DAS28, the CRP level, the RF titer, and the urinary deoxypyridinoline level in RA patients. Successful treatment of RA reduced serum sSema4D levels, and reductions in the sSema4D level were significantly correlated with reductions in clinical disease activity as measured by the DAS28. Collectively, these results suggest that sSema4D is a potentially useful biomarker for RA disease activity. In addition, serum sSema4D levels were correlated with levels of CRP, a well-known acute-phase protein induced by proinflammatory cytokines such as IL-1β, IL-6, and TNFα (43). Because sSema4D induced IL-6 and TNFα production from CD14+ monocytes, it is possible that sSema4D affects CRP production via induction of IL-6 and TNFα in RA patients. The RF titer was also correlated with serum sSema4D levels. Given that Sema4D has been implicated in activation of B cells and antibody production (28,31), sSema4D may be directly relevant to RF production.

Recent work showed that Sema4D expressed in osteoclasts inhibits bone regeneration by inhibiting osteoblasts (15). Consistent with this, we found that some bone metabolic markers were correlated with serum sSema4D levels in RA (Table 1). The bone formation marker BAP and the bone resorption marker urinary deoxypyridinoline were correlated with serum sSema4D levels. However, other bone formation markers (such as osteocalcin) and bone resorption markers (such as C-terminal crosslinking telopeptide of type I collagen and serum N-telopeptide of type I collagen) were not correlated with serum sSema4D levels. The relationship between serum sSema4D levels and bone metabolic markers in RA patients is a subject of controversy, although the local concentration of Sema4D may be relevant to joint destruction in RA. Further studies will be needed to determine the importance of Sema4D in bone destruction in RA.

Because Sema4D is strongly expressed in immune cells (24), we initially assumed that elevated expression of Sema4D explained the increase in sSema4D in RA serum and synovial fluid. Contrary to our expectation, however, fluorescence-activated cell sorting analysis revealed that levels of Sema4D were actually reduced in lymphocytes and monocytes from the peripheral blood of RA patients. Because expression of Sema4D mRNA was stable in all cells, it is likely that
the relative reduction in cellular levels of Sema4D was due to cleavage and shedding of Sema4D from the cell surface. In support of this notion, a previous study showed that EDTA, an inhibitor of metalloproteinases, inhibits sSema4D secretion, suggesting that sSema4D is produced via a shedding mechanism (27). Other studies showed that ADAM-17 regulates Sema4D exodomain cleavage on activated platelets (44,45). Taken together, the results of these studies prompted us to investigate the generation and function of Sema4D.

We examined several proteolytic enzymes as candidate sheddases for sSema4D. Proteolytic enzymes such as ADAMTS, ADAMs, and MMPs influence inflammation and progression of arthritis (46–48). Herein we showed that induction of sSema4D is dependent on ADAMTS-4. Originally, ADAMTS-4 was considered to have a key role in the degradation of cartilage proteoglycan (aggrecan) in OA and RA. Consistent with this, levels of ADAMTS-4 were elevated in RA serum, and TNFα and IL-6 induced the production of ADAMTS-4.

In this study, we demonstrated that production of inflammatory cytokines such as TNFα and IL-6 increased upon stimulation with sSema4D. We also showed that sSema4D induced dephosphorylation of CD72 (see Supplementary Figure 5, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract). CD72 contains an immunoreceptor tyrosine–based inhibition motif in its cytoplasmic region (49). Investigators in our group have previously reported that Sema4D induces dephosphorylation of CD72, turning off its negative signal in B cells (32). It thus appears that Sema4D is involved in cytokine production in monocytes as well.

Our results indicated that sSema4D induces TNFα and IL-6 production and that both TNFα and IL-6 can induce ADAMTS-4, which is involved in generation of sSema4D. Therefore, we hypothesized that the vicious circle of sSema4D/TNFα/IL-6/ADAMTS-4 functions as an autocrine accelerator of the IL-6/TNFα inflammatory axis in RA. It is well known that TNFα and IL-6 induce osteoclastogenesis through RANKL production, and ADAMTS-4 induces cartilage degradation in RA (48). In addition, Sema4D inhibits bone formation (15). Therefore, the autocrine loop involving Sema4D induces cartilage destruction, inhibits bone regeneration, and evokes continuous inflammatory symptoms. This Sema4D loop may have a central role in RA inflammation and the associated joint destruction (see Supplementary Figure 9, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39086/abstract).

We analyzed the effect of anti-Sema4D antibody treatment in a mouse model of inflammatory arthritis. Blocking Sema4D in CIA exerted favorable therapeutic effects, decreasing destruction of cartilage and bone, cell infiltration into the synovium, and production of TNFα and IL-6 (Figure 5). To investigate the therapeutic effects of anti-Sema4D antibody on ongoing arthritis, we administered anti-Sema4D antibody after arthritis had already commenced. These observations suggest that Sema4D represents a possible therapeutic target for treatment of RA. Recently developed biologic DMARDs inhibit TNFα and IL-6 function; however, these therapies do not inhibit cytokine production directly. Therefore, RA flares are often observed after cessation of biologic DMARD therapy. Thus, it seems likely that direct inhibition of TNFα and IL-6 production by anti-Sema4D therapy would be useful for RA management. An anti-Sema4D antibody is currently undergoing a phase I clinical trial (NCT01313065) in cancer patients (50). However, the long-term feasibility of anti-Sema4D antibody is still unknown. Careful and well-designed clinical applications will be needed.

In summary, we demonstrated that serum sSema4D levels are well correlated with known markers of clinical features and laboratory findings. The critical roles of Sema4D in RA pathogenesis suggest that Sema4D is a potential novel target for RA treatment.

ACKNOWLEDGMENTS

We appreciate the patients and healthy volunteers who participated in this research.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Drs. Yoshida and Ogata had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Yoshida, Ogata, Kumanogoh.

Acquisition of data. Yoshida, Ogata, Ebina, Shi, Nojima, Kimura, Ito, Morimoto, Nishide, Hosokawa, Hiran, Shim, Narazaki, Tsuboi, Saeki, Tomita, Tanaka.

Analysis and interpretation of data. Yoshida, Ogata, Kang, Kumanogoh.

REFERENCES

1. Kochi Y, Suzuki A, Yamamoto K. Genetic basis of rheumatoid arthritis: a current review. Biochem Biophys Res Commun 2014;452:254–62.
2. Holmdahl R, Malmstrom V, Burkhart H. Autoimmune priming, tissue attack and chronic inflammation: the three stages of rheumatoid arthritis. Eur J Immunol 2014;44:1593–9.
3. Ogura H, Murakami M, Okuyama Y, Tsuuroka M, Kitabayashi C, Kanamoto M, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008;29:628–36.
4. Zhao W, Zhang C, Shi M, Zhang J, Li M, Xue X, et al. The discoidin domain receptor 2/annexin A2/matrix metalloproteinase 13 loop promotes joint destruction in arthritis through promoting migration and invasion of fibroblast-like synoviocytes. Arthritis Rheumatol 2014;66:2355–67.
5. Cesak G, Kuzawinska O, Burda A, Lis K, Wojnar M, Mirowska-Guzel D, et al. TNF inhibitors: mechanisms of action, approved and off-label indications. Pharmacol Rep 2014;66:836–44.
6. Vadasz Z, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int 2014;2014:698313.

7. Kolidon KL. Semaphorins: mediators of repulsive growth cone guidance. Trends Cell Biol 1996;6:15–22.

8. Zhou Y, Gunput RA, Pasterkamp RJ. Semaphorin signaling: progress made and promises ahead. Trends Biochem Sci 2008;33:161–70.

9. Takamatsu H, Kumanogoh A. Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol 2012;33:127–35.

10. Kumanogoh A, Kikutani H. Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev Immunol 2013;13:802–14.

11. Vadasz Z, Attias D, Kessel A, Toubi E. Neuropilins and semaphorins: from angiogenesis to autoimmunity. Autoimmun Rev 2010;9:825–9.

12. Gu C, Giraudo E. The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res 2013;319:1306–16.

13. Rehman M, Tamagnone L. Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin Cell Dev Biol 2013;24:179–89.

14. Rizzolio S, Tamagnone L. Semaphorin signals on the road to cancer invasion and metastasis. Cell Adh Migr 2007;1:62–8.

15. Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, FrieDEL RH, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011;17:1473–80.

16. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3A. Nature 2012;485:69–74.

17. Fukuda T, Takeda S, Xu R, Ochi H, Sunamura S, Sato T, et al. Sema3A regulates bone-mass accrual through sensory innervation. Nature 2013;497:490–3.

18. Kumanogoh A, Kikutani H. Immune semaphorins: a new area of semaphorin research. J Cell Sci 2003;116:3463–70.

19. Nakatsuji Y, Okuno T, Moriya M, Sugimoto T, Kodama T, FrieDEL RH, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011;17:1473–80.

20. Xie G, Roshandel D, Sherva R, Monach PA, Lu EY, Kung T, et al. Elevation of Sema4A implicates Th cell signaling in the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int Immunol 2003;15:1027–34.

21. Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, et al. Roles of Sema4D–plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 2010;184:1499–506.

22. Williams-Skipp C, Raman T, Valuck RJ, Watkins H, Palmer BE, Scheinman RI. Unmasking of a protective tumor necrosis factor receptor I–mediated signal in the collagen-induced arthritis model. Arthritis Rheum 2009;60:408–18.

23. Xie G, Roshandel D, Sherva R, Monach PA, Lu EY, Kung T, et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA–DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum 2013;65:2457–68.

24. Catalano A. The neuroimmune semaphorin–3A releases inflammation and progression of experimental autoimmune arthritis. J Immunol 2010;185:6373–83.

25. Gras C, Eiz-Vesper B, Jaimes Y, Immenschuh S, Jacobs R, Witte T, et al. Secreted semaphorin 5A activates immune effector cells and is a biomarker for rheumatoid arthritis. Arthritis Rheumatol 2014;66:1461–71.

26. Vadasz Z, Haj T, Halasz K, Rosner I, Slobodin G, Attias D, et al. Semaphorin 3A is a marker for disease activity and a potential therapeutic target in rheumatoid arthritis. J Immunol 1992;148:518–23.

27. Elhabazi A, Marie-Cardine A, Chabbert-de Ponnat I, Bensussan A, Boumell L. Structure and function of the immune semaphorin CD100/SEMA4D. Crit Rev Immunol 2003;23:65–81.

28. Elhabazi A, Delaire S, Bensussan A, Boumell L, Bismuth G. Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis. J Immunol 2001;166:4341–7.

29. Wang X, Kumanogoh A, Watanabe C, Shi W, Yoshida K, Kikutani H. Functional soluble CD100/CD40 released from activated lymphocytes: possible role in normal and pathologic immune responses. Blood 2001;97:3408–504.

30. Ji JD, Ivashik LB. Roles of semaphorins in the immune and hematopoietic system. Rheumatol Int 2009;29:727–34.